These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15767976)

  • 21. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
    Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P
    BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New treatment options for overactive bladder.
    Oehlke KJ
    S D J Med; 2005 Jun; 58(6):225-6. PubMed ID: 16050656
    [No Abstract]   [Full Text] [Related]  

  • 23. Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.
    Staskin DR; MacDiarmid SA
    Am J Med; 2006 Mar; 119(3 Suppl 1):9-15. PubMed ID: 16483863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solifenacin succinate for the treatment of symptoms of overactive bladder.
    Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
    Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Darifenacin: Pharmacology and clinical usage.
    Steers WD
    Urol Clin North Am; 2006 Nov; 33(4):475-82, viii. PubMed ID: 17011383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Solifenacin in overactive bladder syndrome.
    Simpson D; Wagstaff AJ
    Drugs Aging; 2005; 22(12):1061-9. PubMed ID: 16363887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Urinary incontinence: new pharmacologic therapies].
    Robles García JE; Zudaire Bergera JJ; Rosell Costa D; Berián Polo JM
    Rev Med Univ Navarra; 2004; 48(4):43-9. PubMed ID: 15812946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
    Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
    J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
    Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
    Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.
    Zinner N; Susset J; Gittelman M; Arguinzoniz M; Rekeda L; Haab F
    Int J Clin Pract; 2006 Jan; 60(1):119-26. PubMed ID: 16409440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.
    Chapple C; DuBeau C; Ebinger U; Rekeda L; Viegas A
    Curr Med Res Opin; 2007 Oct; 23(10):2347-58. PubMed ID: 17706004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
    Ohtake A; Ukai M; Hatanaka T; Kobayashi S; Ikeda K; Sato S; Miyata K; Sasamata M
    Eur J Pharmacol; 2004 May; 492(2-3):243-50. PubMed ID: 15178371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solifenacin: scientific evidence in the treatment of overactive bladder.
    Santos JC; Telo ER
    Arch Esp Urol; 2010 Apr; 63(3):197-213. PubMed ID: 20431184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis.
    Abrams P; Swift S
    Eur Urol; 2005 Sep; 48(3):483-7. PubMed ID: 16005564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
    Hill S; Khullar V; Wyndaele JJ; Lheritier K;
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 May; 17(3):239-47. PubMed ID: 15999217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database.
    Mauseth SA; Skurtveit S; Spigset O
    Acta Obstet Gynecol Scand; 2013 Oct; 92(10):1208-15. PubMed ID: 23763552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Darifenacin in the treatment of overactive bladder.
    Haab F
    Drugs Today (Barc); 2005 Jul; 41(7):441-52. PubMed ID: 16193097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis.
    Drinka PJ
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):292-3; author reply 293. PubMed ID: 17062331
    [No Abstract]   [Full Text] [Related]  

  • 39. [A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder].
    Cardozo L; Lisec M; Milard R; Van Vierssen Trip O; Kuzmin I; Drogendijk TE; Huang AM
    Akush Ginekol (Sofiia); 2007; 46(5):55-7. PubMed ID: 17974184
    [No Abstract]   [Full Text] [Related]  

  • 40. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
    Jonas U; Rackley RR
    Eur Urol; 2006 Jan; 49(1):187-8; author reply 188-90. PubMed ID: 16310930
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.